(Q36463078)

14 August 2017

title

Complications of a temozolomide overdose: a case report (English)

1 reference

14 August 2017

1 reference

0 references

2

Hans-Peter Kiem

1 reference

14 August 2017

Alexander M Spence

1

1 reference

14 August 2017

Sonia Partap

3

1 reference

14 August 2017

Scott Schuetze

4

1 reference

14 August 2017

John R Silber

5

1 reference

14 August 2017

Richard A Peterson

6

1 reference

14 August 2017

publication date

28 April 2006

1 reference

Journal of Neuro-Oncology

14 August 2017

published in

1 reference

14 August 2017

volume

80

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

57-61

1 reference

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

14 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-006-9152-Y

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-006-9152-Y

High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11060-006-9152-Y

High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience.

21 January 2018

1 reference

12 December 2020

A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors

1 reference

12 December 2020

Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide

1 reference

12 December 2020

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

1 reference

12 December 2020

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

1 reference

12 December 2020

Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma

1 reference

12 December 2020

High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.

1 reference

12 December 2020

CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future

1 reference

12 December 2020

Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study

1 reference

12 December 2020

High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.

1 reference

12 December 2020

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer

1 reference

12 December 2020

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

12 December 2020

O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy

1 reference

12 December 2020

Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy

1 reference

12 December 2020

Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.

1 reference

12 December 2020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

12 December 2020

10.1007/S11060-006-9152-Y

Identifiers

DOI

1 reference

14 August 2017

1 reference